https://www.selleckchem.com/products/a-366.html
Patients were followed-up to determine Objective Response Rate (ORR), Progression Free Survival (PFS) and Overall Survival (OS). Results The Objective Response Rate (ORR) was 57.1%, the disease Control rate (DCR) was 91.8%, median Progression Free Survival (mPFS) was 4.9 months and median Overall Survival (mOS) was 9.4 months. There were no Grade IV treatment related adverse events (AEs) or any treatment related deaths. Conclusion Patient-specific combination regimens with mTOR inhibition and other anti-neoplastic agents, when selected ba
Mi piace
Commento
Condividi
